Paclitaxel and immune system

European Journal of Pharmaceutical Sciences

Volumn 38, Issue 4, 2009, Pages 283-290

  Javeed, Aqeel ^a   Ashraf, Muhammad ^a   Riaz, Amjad ^a   Ghafoor, Aamir ^b   Afzal, Sheryar ^a   Mukhtar, Muhammad Mahmood ^a  

^a UNIVERSITY OF VETERINARY AND ANIMAL SCIENCES   (Pakistan)

^b MASSEY UNIVERSITY   (New Zealand)

Author keywords

Autoimmune disorders; Immune; Paclitaxel; Transplantation; Tumor

Indexed keywords

AGATOLIMOD; ALPHA INTERFERON; ANTIMITOTIC AGENT; ANTINEOPLASTIC AGENT; CYANOCOBALAMIN; CYCLOPHOSPHAMIDE; CYCLOSPORIN; DENDRITIC CELL VACCINE; DNA VACCINE; DOCETAXEL; DOXORUBICIN; ISOTRETINOIN; N METHYLTRYPTOPHAN; ORTATAXEL; PACLITAXEL; PF 3512675; RECOMBINANT INTERLEUKIN 12; TAXANE DERIVATIVE; TRASTUZUMAB; TUBULIN; TUMOR VACCINE; UNCLASSIFIED DRUG;

ALLERGIC ENCEPHALOMYELITIS; ANTINEOPLASTIC ACTIVITY; AUTOIMMUNE DISEASE; B LYMPHOCYTE; BREAST CANCER; CANCER CHEMOTHERAPY; DENDRITIC CELL; DISEASE FREE SURVIVAL; DRUG ELIMINATION; DRUG HALF LIFE; DRUG MECHANISM; EARLY CANCER; GRAFT REJECTION; HUMAN; IMMUNE SYSTEM; IMMUNOCOMPETENT CELL; IMMUNOMODULATION; IMMUNOSTIMULATION; KAPOSI SARCOMA; KIDNEY CARCINOMA; LOW DRUG DOSE; LUNG NON SMALL CELL CANCER; LYMPHOCYTE ACTIVATION; MACROPHAGE; METASTASIS; MICROTUBULE; MITOSIS INHIBITION; NATURAL KILLER CELL; NONHUMAN; ORGAN TRANSPLANTATION; OVERALL SURVIVAL; PRIORITY JOURNAL; PROTEIN BINDING; REVIEW; T LYMPHOCYTE;

ANIMALS; ANTINEOPLASTIC AGENTS; AUTOIMMUNE DISEASES; HUMANS; IMMUNITY, CELLULAR; IMMUNOLOGIC FACTORS; PACLITAXEL; T-LYMPHOCYTES, REGULATORY;

EID: 70349838021     PISSN: 09280987     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ejps.2009.08.009     Document Type: Review

References (105)

1. Abbara C., Rouchon C., Hosten B., Farinotti R., and Bonhomme-Faivre L. Enhanced oral bioavailability of paclitaxel by recombinant interleukin-2 in mice with murine Lewis lung carcinoma. Drug Metabol. Drug Interact. 20 (2004) 219-231
2. Albers A.E., Ferris R.L., Kim G.G., Chikamatsu K., DeLeo A.B., and Whiteside T.L. Immune responses to p53 in patients with cancer: enrichment in tetramer+ p53 peptide-specific T cells and regulatory T cells at tumor sites. Cancer Immunol. Immunother. 54 (2005) 1072-1081
3. Amato S.F., Swart J.M., Berg M., Wanebo H.J., Mehta S.R., and Chiles T.C. Transient stimulation of the c-Jun-NH2-terminal kinase/activator protein 1 pathway and inhibition of extracellular signal-regulated kinase are early effects in paclitaxel-mediated apoptosis in human B lymphoblasts. Cancer Res. 58 (1998) 241-247
4. Arsenault A.L., Lhotak S., Hunter W.L., Banquerigo M.L., and Brahn E. Taxol involution of collagen-induced arthritis: ultrastructural correlation with the inhibition of synovitis and neovascularization. Clin. Immunol. Immunopathol. 86 (1998) 280-289
5. Arsenault A.L., Lhotak S., Hunter W.L., Banquerigo M.L., and Brahn E. Taxol (paclitaxel) involution of articular cartilage destruction in collagen induced arthritis: an ultrastructural demonstration of an increased superficial chondroprotective layer. J. Rheumatol. 27 (2000) 582-588
6. Azzoli C.G., Krug L.M., Gomez J., Miller V.A., Kris M.G., Ginsberg M.S., Henry R., Jones J., Tyson L., Dunne M., Pizzo B., Farmer A., Venkatraman E., Steffen R., and Sirotnak F.M. A phase 1 study of pralatrexate in combination with paclitaxel or docetaxel in patients with advanced solid tumors. Clin. Cancer Res. 13 (2007) 2692-2698
7. Bhan V., Mader J.S., and Hoskin D.W. In vitro exposure to paclitaxel modulates integrin expression by human T lymphocytes and inhibits T cell adhesion to breast carcinoma cells. Oncol. Rep. 11 (2004) 893-897
8. Brahn E., Tang C., and Banquerigo M.L. Regression of collagen-induced arthritis with taxol, a microtubule stabilizer. Arthritis Rheum. 37 (1994) 839-845
9. Byrd-Leifer C.A., Block E.F., Takeda K., Akira S., and Ding A. The role of MyD88 and TLR4 in the LPS-mimetic activity of Taxol. Eur. J. Immunol. 31 (2001) 2448-2457
10. Cao L., Sun D., Cruz T., Moscarello M.A., Ludwin S.K., and Whitaker J.N. Inhibition of experimental allergic encephalomyelitis in the Lewis rat by paclitaxel. J. Neuroimmunol. 108 (2000) 103-111
11. Cassidy P.B., Moos P.J., Kelly R.C., and Fitzpatrick F.A. Cyclooxygenase-2 induction by paclitaxel, docetaxel, and taxane analogues in human monocytes and murine macrophages: structure-activity relationships and their implications. Clin. Cancer Res. 8 (2002) 846-855
12. Chan O.T., and Yang L.X. The immunological effects of taxanes. Cancer Immunol. Immunother. 49 (2000) 181-185
13. Chen Y.M., Yang W.K., Ting C.C., Yang D.M., Whang-Peng J., and Perng R.P. Depressed cytolytic activity of peripheral blood mononuclear cells in unusually high paclitaxel concentrations: reversal by IL-2 and IL-12. Zhonghua Yi Xue Za Zhi (Taipei) 62 (1999) 867-874
14. Chopra A., Kim T.S.I.O.S., Martinez D., and Cohen E.P. Combined therapy of an established, highly aggressive breast cancer in mice with paclitaxel and a unique DNA-based cell vaccine. Int. J. Cancer 118 (2006) 2888-2898
15. Clavarezza M., Del Mastro L., and Venturini M. Taxane-containing chemotherapy in the treatment of early breast cancer patients. Ann. Oncol. 17 Suppl. 7 (2006) vii22-vii26
16. Collins T.S., Lee L.F., and Ting J.P. Paclitaxel up-regulates interleukin-8 synthesis in human lung carcinoma through an NF-kappaB- and AP-1-dependent mechanism. Cancer Immunol. Immunother. 49 (2000) 78-84
17. Condeelis J., and Pollard J.W. Macrophages: obligate partners for tumor cell migration, invasion, and metastasis. Cell 124 (2006) 263-266
18. Consolini R., Pui C.H., Behm F.G., Raimondi S.C., and Campana D. In vitro cytotoxicity of docetaxel in childhood acute leukemias. J. Clin. Oncol. 16 (1998) 907-913
19. Crown J., and O'Leary M. The taxanes: an update. Lancet 355 (2000) 1176-1178
20. Cvetkovic I., Miljkovic D., Vuckovic O., Harhaji L., Nikolic Z., Trajkovic V., and Mostarica Stojkovic M. Taxol activates inducible nitric oxide synthase in rat astrocytes: the role of MAP kinases and NF-kappaB. Cell. Mol. Life Sci. 61 (2004) 1167-1175
21. Dang C., and Hudis C. Adjuvant taxanes in the treatment of breast cancer: no longer at the tip of the iceberg. Clin. Breast Cancer 7 (2006) 51-58
22. De Laurentiis M., Cancello G., D'Agostino D., Giuliano M., Giordano A., Montagna E., Lauria R., Forestieri V., Esposito A., Silvestro L., Pennacchio R., Criscitiello C., Montanino A., Limite G., Bianco A.R., and De Placido S. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials. J. Clin. Oncol. 26 (2008) 44-53
23. Derin D., Soydinc H.O., Guney N., Tas F., Camlica H., Duranyildiz D., Yasasever V., and Topuz E. Serum IL-8 and IL-12 levels in breast cancer. Med. Oncol. 24 (2007) 163-168
24. Donaldson K.L., Goolsby G.L., and Wahl A.F. Cytotoxicity of the anticancer agents cisplatin and taxol during cell proliferation and the cell cycle. Int. J. Cancer 57 (1994) 847-855
25. Dunn G.P., Old L.J., and Schreiber R.D. The immunobiology of cancer immunosurveillance and immunoediting. Immunity 21 (2004) 137-148
26. Dunn G.P., Old L.J., and Schreiber R.D. The three Es of cancer immunoediting. Annu. Rev. Immunol. 22 (2004) 329-360
27. Dustin P. Microtubules. Sci. Am. 243 (1980) 66-76
28. Emens L.A., and Jaffee E.M. Leveraging the activity of tumor vaccines with cytotoxic chemotherapy. Cancer Res. 65 (2005) 8059-8064
29. Fitzpatrick F.A., and Wheeler R. The immunopharmacology of paclitaxel (Taxol), docetaxel (Taxotere), and related agents. Int. Immunopharmacol. 3 (2003) 1699-1714
30. Gavin M., and Rudensky A. Control of immune homeostasis by naturally arising regulatory CD4+ T cells. Curr. Opin. Immunol. 15 (2003) 690-696
31. Gong J., Avigan D., Chen D., Wu Z., Koido S., Kashiwaba M., and Kufe D. Activation of antitumor cytotoxic T lymphocytes by fusions of human dendritic cells and breast carcinoma cells. Proc. Natl. Acad. Sci. U.S.A. 97 (2000) 2715-2718
32. Hernandez-Vargas H., Palacios J., and Moreno-Bueno G. Telling cells how to die: docetaxel therapy in cancer cell lines. Cell Cycle 6 (2007) 780-783
33. Hortobagyi G.N. Recent progress in the clinical development of docetaxel (Taxotere). Semin. Oncol. 26 (1999) 32-36
34. Iesalnieks I., Tange S., Scherer M.N., Graeb C., Frank E., Jauch K.W., and Geissler E.K. Paclitaxel promotes liver graft survival in rats and inhibits hepatocellular carcinoma growth in vitro and is a potentially useful drug for transplant patients with liver cancer. Transplant. Proc. 34 (2002) 2316-2317
35. Imataki O., Makimoto A., Kojima R., Sakiyama M., Hosono A., and Takaue Y. Intensive multimodality therapy including paclitaxel and reduced-intensity allogeneic hematopoietic stem cell transplantation in the treatment of adrenal cancer with multiple metastases. Int. J. Clin. Oncol./Jpn. Soc. Clin. Oncol. 11 (2006) 156-158
36. Jazirehi A.R., Gan X.H., De Vos S., Emmanouilides C., and Bonavida B. Rituximab (anti-CD20) selectively modifies Bcl-xL and apoptosis protease activating factor-1 (Apaf-1) expression and sensitizes human non-Hodgkin's lymphoma B cell lines to paclitaxel-induced apoptosis. Mol. Cancer Ther. 2 (2003) 1183-1193
37. Joo H.G. Altered maturation of dendritic cells by taxol, an anticancer drug. J. Vet. Sci. 4 (2003) 229-234
38. Jordan M.A., and Wilson L. Microtubules as a target for anticancer drugs. Nat. Rev. Cancer 4 (2004) 253-265
39. Kashimura S., Terashima M., Soeta N., Otani S., Hoshino M., Kanzaki N., Matsuyama S., Hoshino Y., Kogure M., Gotoh M., Ogata T., and Ohto H. Experimental study for a combination chemo-immunotherapy using dendritic cells. Gan To Kagaku Ryoho 31 (2004) 1631-1633
40. Kim M., Park I.Y., Lim J., Kim Y., Han K.T., Chung W.H., and Han K. Antitumor and normal cell protective effect of PKC412 in the athymic mouse model of ovarian cancer. Ann. Clin. Lab. Sci. 36 (2006) 455-460
41. Kim Y.M., and Paik S.G. Induction of expression of inducible nitric oxide synthase by Taxol in murine macrophage cells. Biochem. Biophys. Res. Commun. 326 (2005) 410-416
42. Kirikae T., Ojima I., Fuero-Oderda C., Lin S., Kirikae F., Hashimoto M., and Nakanoc M. Structural significance of the acyl group at the C-10 position and the A ring of the taxane core of paclitaxel for inducing nitric oxide and tumor necrosis factor production by murine macrophages. FEBS Lett. 478 (2000) 221-226
43. Kirkwood J.M., Ibrahim J.G., Sondak V.K., Richards J., Flaherty L.E., Ernstoff M.S., Smith T.J., Rao U., Steele M., and Blum R.H. High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J. Clin. Oncol. 18 (2000) 2444-2458
44. Klebanoff C.A., Khong H.T., Antony P.A., Palmer D.C., and Restifo N.P. Sinks, suppressors and antigen presenters: how lymphodepletion enhances T cell-mediated tumor immunotherapy. Trends Immunol. 26 (2005) 111-117
45. Kubo M., Morisaki T., Matsumoto K., Tasaki A., Yamanaka N., Nakashima H., Kuroki H., Nakamura K., Nakamura M., and Katano M. Paclitaxel probably enhances cytotoxicity of natural killer cells against breast carcinoma cells by increasing perforin production. Cancer Immunol. Immunother. 54 (2005) 468-476
46. Kurose A., Yoshida W., Yoshida M., and Sawai T. Effects of paclitaxel on cultured synovial cells from patients with rheumatoid arthritis. Cytometry 44 (2001) 349-354
47. Lee B.H., Lee J.E., Lee K.W., Nam H.Y., Jeon H.J., Sung Y.J., Kim J.S., Lim H.J., Park J.S., Ko J.Y., and Kim D.J. Coating with paclitaxel improves graft survival in a porcine model of haemodialysis graft stenosis. Nephrol. Dial. Transplant. 22 (2007) 2800-2804
48. Lee M., and Jeon Y.J. Paclitaxel-induced immune suppression is associated with NF-kappaB activation via conventional PKC isotypes in lipopolysaccharide-stimulated 70Z/3 pre-B lymphocyte tumor cells. Mol. Pharmacol. 59 (2001) 248-253
49. Lee M., Yea S.S., and Jeon Y.J. Paclitaxel causes mouse splenic lymphocytes to a state hyporesponsive to lipopolysaccharide stimulation. Int. J. Immunopharmacol. 22 (2000) 615-621
50. Lilleby W., and Fossa S.D. Chemotherapy in metastatic renal cell cancer. World J. Urol. 23 (2005) 175-179
51. Lin C.K., Nguyen T.T., Morgan T.L., Mei R.L., Kaptein J.S., Kalunta C.I., Yen C.F., Park E., Zou H.Y., and Lad P.M. Apoptosis may be either suppressed or enhanced with strategic combinations of antineoplastic drugs or anti-IgM. Exp. Cell Res. 244 (1998) 1-13
52. Loubani O., and Hoskin D.W. Paclitaxel inhibits natural killer cell binding to target cells by down-regulating adhesion molecule expression. Anticancer Res. 25 (2005) 735-741
53. Machiels J.P., Reilly R.T., Emens L.A., Ercolini A.M., Lei R.Y., Weintraub D., Okoye F.I., and Jaffee E.M. Cyclophosphamide, doxorubicin, and paclitaxel enhance the antitumor immune response of granulocyte/macrophage-colony stimulating factor-secreting whole-cell vaccines in HER-2/neu tolerized mice. Cancer Res. 61 (2001) 3689-3697
54. Manthey C.L., Qureshi N., Stutz P.L., and Vogel S.N. Lipopolysaccharide antagonists block taxol-induced signaling in murine macrophages. J. Exp. Med. 178 (1993) 695-702
55. Markasz L., Stuber G., Vanherberghen B., Flaberg E., Olah E., Carbone E., Eksborg S., Klein E., Skribek H., and Szekely L. Effect of frequently used chemotherapeutic drugs on the cytotoxic activity of human natural killer cells. Mol. Cancer Ther. 6 (2007) 644-654
56. Mastronardi F.G., Tsui H., Winer S., Wood D.D., Selvanantham T., Galligan C., Fish E.N., Dosch H.M., and Moscarello M.A. Synergy between paclitaxel plus an exogenous methyl donor in the suppression of murine demyelinating diseases. Mult. Scler. (Houndmills, Basingstoke, England) 13 (2007) 596-609
57. Mehta S., Blackinton D., Manfredi M., Rajaratnam D., Kouttab N., and Wanebo H. Taxol pretreatment of tumor targets amplifies natural killer cell mediated lysis. Leuk. Lymphoma 26 (1997) 67-76
58. Melichar B., Touskova M., Dvorak J., Jandik P., and Kopecky O. The peripheral blood leukocyte phenotype in patients with breast cancer: effect of doxorubicin/paclitaxel combination chemotherapy. Immunopharmacol. Immunotoxicol. 23 (2001) 163-173
59. Moos P.J., and Fitzpatrick F.A. Taxane-mediated gene induction is independent of microtubule stabilization: induction of transcription regulators and enzymes that modulate inflammation and apoptosis. Proc. Natl. Acad. Sci. U.S.A. 95 (1998) 3896-3901
60. Muller A.J., DuHadaway J.B., Donover P.S., Sutanto-Ward E., and Prendergast G.C. Inhibition of indoleamine 2,3-dioxygenase, an immunoregulatory target of the cancer suppression gene Bin1, potentiates cancer chemotherapy. Nat. Med. 11 (2005) 312-319
61. Mullins D.W., Burger C.J., and Elgert K.D. Paclitaxel enhances macrophage IL-12 production in tumor-bearing hosts through nitric oxide. J. Immunol. 162 (1999) 6811-6818
62. Mullins D.W., Koci M.D., Burger C.J., and Elgert K.D. Interleukin-12 overcomes paclitaxel-mediated suppression of T-cell proliferation. Immunopharmacol. Immunotoxicol. 20 (1998) 473-492
63. Mullins D.W., Martins R.S., Burger C.J., and Elgert K.D. Tumor cell-derived TGF-beta and IL-10 dysregulate paclitaxel-induced macrophage activation. J. Leukoc. Biol. 69 (2001) 129-137
64. Nishikawa H., Kato T., Tawara I., Takemitsu T., Saito K., Wang L., Ikarashi Y., Wakasugi H., Nakayama T., Taniguchi M., Kuribayashi K., Old L.J., and Shiku H. Accelerated chemically induced tumor development mediated by CD4+CD25+ regulatory T cells in wild-type hosts. Proc. Natl. Acad. Sci. U.S.A. 102 (2005) 9253-9257
65. Oliver S.J., Banquerigo M.L., and Brahn E. Suppression of collagen-induced arthritis using an angiogenesis inhibitor, AGM-1470, and a microtubule stabilizer, taxol. Cell. Immunol. 157 (1994) 291-299
66. Pardoll D. Does the immune system see tumors as foreign or self?. Annu. Rev. Immunol. 21 (2003) 807-839
67. Parness J., and Horwitz S.B. Taxol binds to polymerized tubulin in vitro. J. Cell Biol. 91 (1981) 479-487
68. Patel N., Salifu M., Sumrani N., Distant D., Hong J., Markell M., and Braverman A.S. Successful treatment of post-renal transplant Kaposi's sarcoma with paclitaxel. Am. J. Transplant. 2 (2002) 877-879
69. Piccirillo C.A., and Shevach E.M. Naturally-occurring CD4+CD25+ immunoregulatory T cells: central players in the arena of peripheral tolerance. Semin. Immunol. 16 (2004) 81-88
70. Pressley J.S., and Elgert K.D. Post-chemotherapeutic administration of interleukin-12 retards tumor growth and enhances immune cell function: combination therapy using paclitaxel and IL-12. Cancer Invest. 24 (2006) 351-359
71. Reyes-Corona J., Gonzalez-Huezo M.S., Zea-Medina M.V., Zamora-Valdes D., Victoria-Campos J.L., and Mondragon-Sanchez R.J. Paclitaxel coated-stent for early-onset thrombosis after liver transplantation. Ann. Hepatol. 6 (2007) 272-275
72. Rosenberg S.A. Progress in human tumour immunology and immunotherapy. Nature 411 (2001) 380-384
73. Rovere P., Vallinoto C., Bondanza A., Crosti M.C., Rescigno M., Ricciardi-Castagnoli P., Rugarli C., and Manfredi A.A. Bystander apoptosis triggers dendritic cell maturation and antigen-presenting function. J. Immunol. 161 (1998) 4467-4471
74. Sakaguchi S. Naturally arising CD4+ regulatory t cells for immunologic self-tolerance and negative control of immune responses. Annu. Rev. Immunol. 22 (2004) 531-562
75. Sakaguchi S., Sakaguchi N., Shimizu J., Yamazaki S., Sakihama T., Itoh M., Kuniyasu Y., Nomura T., Toda M., and Takahashi T. Immunologic tolerance maintained by CD25+ CD4+ regulatory T cells: their common role in controlling autoimmunity, tumor immunity, and transplantation tolerance. Immunol. Rev. 182 (2001) 18-32
76. Sako T., Burioka N., Yasuda K., Tomita K., Miyata M., Kurai J., Chikumi H., Watanabe M., Suyama H., Fukuoka Y., Ueda Y., and Shimizu E. Cellular immune profile in patients with non-small cell lung cancer after weekly paclitaxel therapy. Acta Oncol. 43 (2004) 15-19
77. Sano D., Matsuda H., Ishiguro Y., Nishimura G., Kawakami M., and Tsukuda M. Antitumor effects of IDN5109 on head and neck squamous cell carcinoma. Oncol. Rep. 15 (2006) 329-334
78. Sardella G., De Luca L., Di Roma A., De Persio G., Conti G., Paroli M., and Fedele F. Comparison between sirolimus- and paclitaxel-eluting stent in T-cell subsets redistribution. Am. J. Cardiol. 97 (2006) 494-498
79. Schiff P.B., Fant J., and Horwitz S.B. Promotion of microtubule assembly in vitro by taxol. Nature 277 (1979) 665-667
80. Shin H.J., Kim Y.S., Kwak Y.S., Song Y.B., Kim Y.S., and Park J.D. Enhancement of antitumor effects of paclitaxel (taxol) in combination with red ginseng acidic polysaccharide (RGAP). Planta Med. 70 (2004) 1033-1038
81. Song S.Y., and Kim H.S. Strategies to improve dendritic cell-based immunotherapy against cancer. Yonsei Med. J. 45 Suppl. (2004) 48-52
82. Song Y.W., Kim H.A., Baek H.J., Lee E.B., Chung E.S., and Hong K.M. Paclitaxel reduces anti-dsDNA antibody titer and BUN, prolonging survival in murine lupus. Int. J. Immunopharmacol. 20 (1998) 669-677
83. Spencer C.M., and Faulds D. Paclitaxel. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic potential in the treatment of cancer. Drugs 48 (1994) 794-847
84. Subleski J.J., Hall V.L., Back T.C., Ortaldo J.R., and Wiltrout R.H. Enhanced antitumor response by divergent modulation of natural killer and natural killer T cells in the liver. Cancer Res. 66 (2006) 11005-11012
85. Tange S., Scherer M.N., Graeb C., Andrassy J., Justl M., Frank E., Jauch K.W., and Geissler E.K. Paclitaxel saves rat heart allografts from rejection by inhibition of the primed anti-donor humoral and cellular immune response: implications for transplant patients with cancer. Transpl. Int. 16 (2003) 471-475
86. Tange S., Scherer M.N., Graeb C., Weiss T., Justl M., Frank E., Andrassy J., Jauch K.W., and Geissler E.K. The antineoplastic drug paclitaxel has immunosuppressive properties that can effectively promote allograft survival in a rat heart transplant model. Transplantation 73 (2002) 216-223
87. Tong A.W., Seamour B., Lawson J.M., Ordonez G., Vukelja S., Hyman W., Richards D., Stein L., Maples P.B., and Nemunaitis J. Cellular immune profile of patients with advanced cancer before and after taxane treatment. Am. J. Clin. Oncol. 23 (2000) 463-472
88. Tsavaris N., Kosmas C., Vadiaka M., Kanelopoulos P., and Boulamatsis D. Immune changes in patients with advanced breast cancer undergoing chemotherapy with taxanes. Br. J. Cancer 87 (2002) 21-27
89. Tsuda N., Chang D.Z., Mine T., Efferson C., Garcia-Sastre A., Wang X., Ferrone S., and Ioannides C.G. Taxol increases the amount and T cell activating ability of self-immune stimulatory multimolecular complexes found in ovarian cancer cells. Cancer Res. 67 (2007) 8378-8387
90. Turk M.J., Wolchok J.D., Guevara-Patino J.A., Goldberg S.M., and Houghton A.N. Multiple pathways to tumor immunity and concomitant autoimmunity. Immunol. Rev. 188 (2002) 122-135
91. Vassileva V., Allen C.J., and Piquette-Miller M. Effects of sustained and intermittent paclitaxel therapy on tumor repopulation in ovarian cancer. Mol. Cancer Ther. 7 (2008) 630-637
92. Vicari A.P., Luu R., Zhang N., Patel S., Makinen S.R., Hanson D.C., Weeratna R.D., and Krieg A.M. Paclitaxel reduces regulatory T cell numbers and inhibitory function and enhances the anti-tumor effects of the TLR9 agonist PF-3512676 in the mouse. Cancer Immunol. Immunother. 58 (2009) 615-628
93. Wang J., Kobayashi M., Han M., Choi S., Takano M., Hashino S., Tanaka J., Kondoh T., Kawamura K., and Hosokawa M. MyD88 is involved in the signalling pathway for Taxol-induced apoptosis and TNF-alpha expression in human myelomonocytic cells. Br. J. Haematol. 118 (2002) 638-645
94. Wani M.C., Taylor H.L., Wall M.E., Coggon P., and McPhail A.T. Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J. Am. Chem. Soc. 93 (1971) 2325-2327
95. Watson J.M., Kingston D.G., Chordia M.D., Chaudhary A.G., Rinehart C.A., and Haskill J.S. Identification of the structural region of taxol that may be responsible for cytokine gene induction and cytotoxicity in human ovarian cancer cells. Cancer Chemother. Pharmacol. 41 (1998) 391-397
96. Woo E.Y., Chu C.S., Goletz T.J., Schlienger K., Yeh H., Coukos G., Rubin S.C., Kaiser L.R., and June C.H. Regulatory CD4(+)CD25(+) T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res. 61 (2001) 4766-4772
97. Yamori T., Sato S., Chikazawa H., and Kadota T. Anti-tumor efficacy of paclitaxel against human lung cancer xenografts. Jpn. J. Cancer Res. 88 (1997) 1205-1210
98. Yoo W.H., and Baek H.S. Remission of rheumatoid arthritis with taxol in a patient with breast carcinoma. J. Rheumatol. 27 (2000) 1572-1573
99. Yu B., Kusmartsev S., Cheng F., Paolini M., Nefedova Y., Sotomayor E., and Gabrilovich D. Effective combination of chemotherapy and dendritic cell administration for the treatment of advanced-stage experimental breast cancer. Clin. Cancer Res. 9 (2003) 285-294
100. Yu P., Lee Y., Liu W., Krausz T., Chong A., Schreiber H., and Fu Y.X. Intratumor depletion of CD4+ cells unmasks tumor immunogenicity leading to the rejection of late-stage tumors. J. Exp. Med. 201 (2005) 779-791
101. Zaks-Zilberman M., Zaks T.Z., and Vogel S.N. Induction of proinflammatory and chemokine genes by lipopolysaccharide and paclitaxel (Taxol) in murine and human breast cancer cell lines. Cytokine 15 (2001) 156-165
102. Zhang A.L., Colmenero P., Purath U., Teixeira de Matos C., Hueber W., Klareskog L., Tarner I.H., Engleman E.G., and Soderstrom K. Natural killer cells trigger differentiation of monocytes into dendritic cells. Blood 110 (2007) 2484-2493
103. Zhang L., Dermawan K., Jin M., Liu R., Zheng H., Xu L., Zhang Y., Cai Y., Chu Y., and Xiong S. Differential impairment of regulatory T cells rather than effector T cells by paclitaxel-based chemotherapy. Clin. Immunol. (Orlando, FL) 129 (2008) 219-229
104. Zhong H., Han B., Tourkova I.L., Lokshin A., Rosenbloom A., Shurin M.R., and Shurin G.V. Low-dose paclitaxel prior to intratumoral dendritic cell vaccine modulates intratumoral cytokine network and lung cancer growth. Clin. Cancer Res. 13 (2007) 5455-5462
105. Zou W. Regulatory T cells, tumour immunity and immunotherapy. Nat. Rev. Immunol. 6 (2006) 295-307